Treatment of collagenous tissue with glutaraldehyde and aminodiphosphonate calcification inhibitor

• US 4,553,974 A
• Filed: 08/14/1984
• Issued: 11/19/1985
• Est. Priority Date: 08/14/1984
• Status: Expired due to Fees

• Current Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Original Assignee: Mayo Foundation
• Inventors: Dewanjee, Mrinal K.
• Primary Examiner(s): Clingman, A. Lionel
• Application Number:
  US06/640,725
• Time in Patent Office: 462 Days
• Field of Search: 8/94.11, 8/94.18, 8/94.33
• US Class Current: 8/94.11
• CPC Class Codes: A61K 35/30 Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• CPC Class Codes: A61K 35/34 Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes vascular smooth muscle A61K35/44
• CPC Class Codes: A61K 35/44 Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• CPC Class Codes: A61L 2400/02 Treatment of implants to prevent calcification or mineralisation in vivo
• CPC Class Codes: A61L 27/36 containing ingredients of undetermined constitution or reaction products thereof , e.g. transplant tissue, natural bone, extracellular matrix isolated natural compounds, e.g. collagen A61L27/24
• CPC Class Codes: A61L 27/3687 characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents

Abstract

A process for the treatment of collagenous tissue to adapt it for use in a prosthetic implant and to promote the growth of endothelial cells thereon after implantation comprising treatment with at least one surfactant prior to fixation, treatment with agents which inhibit calcification and agents which resist attack by phagocytic cells and optional treatment with stabilizing agents.

Claims

1. A process for the treatment of collagenous tissue to adapt it for use in a prosthetic implant and to promote the growth of endothelial cells thereon after implantation, which comprises the steps of:

(a) contacting said tissue with at least one surfactant for a time sufficient to substantially completely remove deleterious material and open up the fibrous structure of the collagenous tissue;

(b) washing the resulting fibrous matrix to remove substantially all surfactant;

(c) fixing the washed tissue with glutaraldehyde;

(d) treating the glutaraldehyde-fixed tissue with a calcification-inhibiting agent, an agent which inhibits infiltration and attack by phagocytic cells upon implantation and/or an agent which inhibits infection; and

(e) treating the resulting agent/matrix tissue with a reducing agent to stabilize the bonding of the glutaraldehyde of step (c) and the agent of step (d) to the tissue.

2. A process according to claim 1, in which the collagenous tissue is bovine or porcine pericardial tissue.

3. A process according to claim 1, in which the collagenous tissue is dura mater, fascia lata, valve tissue or vascular graft tissue.

4. A process according to claim 1, in which the surfactant is in the form of an aqueous solution containing 0.5 to 6% by weight of surfactant.

5. A process according to claim 4, in which said surfactant is a mixture of an anionic surfactant and a non-ionic surfactant.

6. A process according to claim 5, in which the anionic surfactant is 1% by weight sodium dodecyl sulfate and the non-ionic surfactant is 1% by weight octylphenoxy polyethoxy ethanol and/or 1% by weight polyoxyethylene (20) sorbitan monooleate.

7. A process according to claim 6, in which the collagenous tissue is contacted with said surfactant solution for about three hours at room temperature.

8. A process according to claim 4, in which the surfactant is an amphoteric surfactant.

9. A process according to claim 1, in which the collagenous tissue is pre-washed with saline solution to remove excess blood and plasma proteins, prior to treatment with surfactant.

10. A process according to claim 1, in which the fibrous matrix of tissue resulting from the surfactant treatment is soaked in aqueous glutaraldehyde solution for a time sufficient to fix the tissue by bonding the glutaraldehyde molecules to substantially all the reactive amino groups present in the protein molecules of the tissue.

11. A process according to claim 10, in which the concentration of glutaraldehyde is 0.25 to 1% by weight.

12. A process according to claim 11, in which the tissue is soaked in 0.5% by weight glutaraldehyde solution in the presence of 0.1M acetate buffer for a period of about three and a half hours, after which excess glutaraldehyde is washed from the tissue.

13. A process according to claim 10, in which the glutaraldehyde-fixed tissue is treated with a calcification-inhibiting agent containing reactive amino groups for a time sufficient to bond substantially all the free reactive groups of the bonded glutaraldehyde molecules to the reactive amino groups of the calcification-inhibiting agent.

14. The process according to claim 13, in which the calcification-inhibiting agent is an amino diphosphonate.

15. A process according to claim 14, in which the amino diphosphonate is selected from compounds of the formula:

##STR4##

16. A process according to claim 15, in which the amino diphosphonate is 3-amino-1-hydroxypropane-1,1-diphosphonic acid of formula (1) and the tissue is soaked in fresh saturated solutions of said amino diphosphonate in distilled water at a pH of 8.0 for three hours per day in each fresh solution over a period of three days.

17. A process according to claim 16, in which the tissue is soaked in glutaraldehyde between each fresh soaking with amino diphosphonate.

18. A process according to claim 14, in which the tissue is further treated with 5 to 10 mg/ml of sodium borohydride to stabilize the bonding of the amino diphosphonate and glutaraldehyde to the protein molecules of the tissue.

19. A process according to claim 10, in which the glutaraldehyde-fixed tissue is treated with (i) an agent which inhibits infiltration and attack by phagocytic cells or (ii) an agent which inhibits infection.

20. A process according to claim 19, in which said agent (i) is a sporin antibiotic having a free reactive amino group or methotrexate and said agent (ii) is cephalosporin C.

21. A process according to claim 19, in which the tissue is treated with sodium borohydride to stabilize the bonding of agent (i) or agent (ii) to the treated tissue.

22. A process for the treatment of collagenous tissue to adapt it for use in a prosthetic implant and to promote the growth of endothelial cells thereon after implantation which comprises the sequential combination of the following steps:

(1) contacting the tissue with at least one surfactant for a time sufficient to substantially completely remove deleterious material and open up the fibrous structure to form a matrix substantially free from lipids, red blood cells, plasma protein, organelles, and dead cell fragments;

(2) rinsing the cleaned fibrous matrix resulting from step 1 with distilled water or saline solution to remove substantially all surfactant;

(3) soaking said matrix in aqueous glutaraldehyde solution for a time sufficient to bond the glutaraldehyde molecules to substantially all the reactive amino groups present in the protein molecules of the tissue;

(4) washing the glutaraldehyde-fixed tissue to remove excess glutaraldehyde;

(5) treating the fixed tissue with an aqueous solution of amino diphosphonate containing reactive amino groups for a time sufficient to bond substantially all the free reactive groups of the bonded glutaraldehyde molecules to the reactive amino groups of the amino diphosphonate;

(6) washing to remove excess amino diphosphonate; and

(7) treating the diphosphonate-bonded tissue matrix with sodium borohydride to stabilize the bonding of the amino diphosphonate and glutaraldehyde to the protein molecules of the tissue; and

(8) washing to remove excess sodium borohydride and, if desired, storing the resulting treated tissue in aqueous formaldehyde for subsequent use.

23. A process according to claim 22, in which the collogenous tissue is bovine or porcine pericardial tissue.

24. A process according to claim 22, in which the collagenous tissue is dura mater, fascia lata, valve tissue or vascular graft tissue.

25. A process according to claim 22, in which said collagenous tissue is pre-washed with isotonic saline solution to remove excess blood and plasma proteins prior to treatment with surfactant in step (1).

26. A process according to claim 22, in which step (1) is carried out with an aqueous solution containing 0.5 to 6% by weight of surfactant.

27. A process according to claim 26, in which said surfactant is a mixture of an anionic surfactant and a non-ionic surfactant.

28. A process according to claim 27, in which the anionic surfactant is 1% by weight sodium dodecyl sulfate and the non-ionic surfactant is 1% by weight octylphenoxy polyethoxy ethanol and/or 1% by weight polyoxyethylene (20) sorbitan monooleate.

29. A process according to claim 28, in which the collagenous tissue is contacted with said surfactant solution for three hours at room temperature.

30. A process according to claim 26, in which the surfactant is an amphoteric surfactant.

31. A process according to claim 22, in which step (3) is conducted in a solution having a glutaraldehyde concentration of 0.25 to 1% by weight.

32. A process according to claim 22, in which step (3) is conducted by soaking the collagenous tissue in 0.5% by weight glutaraldehyde in the presence of 0.1M acetate buffer for a period of about three and a half hours.

33. A process according to claim 22, in which the amino diphosphonate used in step (5) is selected from compounds of the formula:

##STR5##

34. A process according to claim 32, in which the amino diphosphonate is 3-amino-1-hydroxypropane-1,1-diphosphonic acid of formula (1) and the tissue is soaked in fresh saturated solutions of said amino diphosphonate in distilled water at a pH of 8.0 for three hours per day in each fresh solution over a period of three days.

35. A process according to claim 34, in which the tissue is soaked with glutaraldehyde between each fresh soaking with amino diphosphonate.

36. A process according to claim 22, in which step (7) is conducted with a solution having a concentration of sodium borohydride of 5 to 10 mg/ml.

37. A fixed and stabilized collagenous tissue adapted for use in a prosthetic implant produced by a process according to claim 22.

38. A storage-stable pack comprising a tissue according to claim 37 immersed in aqueous formaldehyde solution.